NeuroSense Corporate Presentation 2022 ALS Phase 2b

NeuroSense is developing novel combination therapies for neurodegenerative diseases including ALS, Parkinson's, and Alzheimer's. The company employs an FDA 505(b)(2) regulatory pathway with repurposed approved drugs for multi-targeted treatment approaches, supported by strong pre-clinical results and orphan disease designations.